P. Krammer, I. Behrmann, P. Daniel, J. Dhein, and K. Debatin, Regulation of apoptosis in the immune system, Current Opinion in Immunology, vol.6, issue.2, pp.279-289, 1994.
DOI : 10.1016/0952-7915(94)90102-3

D. Maria, R. Zeuner, A. Eramo, A. Domenichelli, C. Bonci et al., Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1, Nature, vol.401, issue.6752, pp.489-493, 1999.
DOI : 10.1038/46809

M. Koulnis, Y. Liu, K. Hallstrom, and M. Socolovsky, Negative Autoregulation by Fas Stabilizes Adult Erythropoiesis and Accelerates Its Stress Response, PLoS ONE, vol.103, issue.7, p.21192, 2011.
DOI : 10.1371/journal.pone.0021192.s006

Y. Claessens, D. Bouscary, J. Dupont, F. Picard, J. Melle et al., In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis, Blood, vol.99, issue.5, pp.1594-601, 2002.
DOI : 10.1182/blood.V99.5.1594

Y. Claessens, S. Park, A. Dubart-kupperschmitt, V. Mariot, C. Garrido et al., Rescue of early-stage myelodysplastic syndrome-deriving erythroid precursors by the ectopic expression of a dominant-negative form of FADD. Blood, pp.4035-4077, 2005.

E. Hellström-lindberg, R. Negrin, R. Stein, S. Krantz, G. Lindberg et al., Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model, British Journal of Haematology, vol.99, issue.2, pp.344-51, 1997.
DOI : 10.1046/j.1365-2141.1997.4013211.x

N. Casadevall, P. Durieux, S. Dubois, F. Hemery, E. Lepage et al., Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial, Blood, vol.104, issue.2, pp.321-328, 2004.
DOI : 10.1182/blood-2003-07-2252

E. Hellström-lindberg, N. Gulbrandsen, G. Lindberg, T. Ahlgren, I. Dahl et al., A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life, British Journal of Haematology, vol.17, issue.6, pp.1037-1083, 2003.
DOI : 10.1046/j.1365-2141.1996.352889.x

S. Park, S. Grabar, C. Kelaidi, O. Beyne-rauzy, F. Picard et al., Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience, Blood, vol.111, issue.2, pp.574-82, 2008.
DOI : 10.1182/blood-2007-06-096370

T. Westers, C. Alhan, M. Chamuleau, M. Van-der-vorst, C. Eeltink et al., Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment, Blood, vol.115, issue.9, pp.1779-84, 2010.
DOI : 10.1182/blood-2009-08-239749

M. Jädersten, L. Malcovati, I. Dybedal, D. Porta, M. Invernizzi et al., Erythropoietin and Granulocyte-Colony Stimulating Factor Treatment Associated With Improved Survival in Myelodysplastic Syndrome, Journal of Clinical Oncology, vol.26, issue.21, pp.3607-3620, 2008.
DOI : 10.1200/JCO.2007.15.4906

P. Greenberg, Z. Sun, K. Miller, J. Bennett, M. Tallman et al., Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996), Blood, vol.114, issue.12, pp.2393-400, 2009.
DOI : 10.1182/blood-2009-03-211797

E. Frisan, P. Pawlikowska, C. Pierre-eugène, V. Viallon, L. Gibault et al., p-ERK1/2 is a predictive factor of response to erythropoiesis-stimulating agents in low/int-1 myelodysplastic syndromes, Haematologica, vol.95, issue.11, 2010.
DOI : 10.3324/haematol.2010.024349

B. Cheson, P. Greenberg, J. Bennett, B. Lowenberg, P. Wijermans et al., Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood, pp.419-444, 2006.

K. Crew, M. Gammon, M. Terry, F. Zhang, M. Agrawal et al., Genetic polymorphisms in the apoptosis-associated genes FAS and FASL and breast cancer risk, Carcinogenesis, vol.28, issue.12, pp.2548-51, 2007.
DOI : 10.1093/carcin/bgm211

K. Sibley, S. Rollinson, J. Allan, A. Smith, G. Law et al., Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia, Cancer Res, vol.63, pp.4327-4357, 2003.

Y. Lee, S. Bae, S. Choi, J. Ji, and G. Song, Associations between the FAS ???670??A/G and ???1,377??G/A polymorphisms and susceptibility to autoimmune rheumatic diseases: a meta-analysis, Molecular Biology Reports, vol.156, issue.12, 2012.
DOI : 10.1007/s11033-012-1957-5

Q. Huang, J. Wang, and Y. Hu, FAS-670 gene polymorphism and cervical carcinogenesis risk: A meta-analysis. Biomed Rep, pp.889-894, 2013.

S. Ettou, E. Audureau, C. Humbrecht, B. Benet, H. Jammes et al., Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML. Leukemia, pp.2297-2306, 2012.
URL : https://hal.archives-ouvertes.fr/hal-01004302

N. Sunter, K. Scott, R. Hills, D. Grimwade, S. Taylor et al., A functional variant in the core promoter of the CD95 cell death receptor gene predicts prognosis in acute promyelocytic leukemia, Blood, vol.119, issue.1, pp.196-205, 2012.
DOI : 10.1182/blood-2011-04-349803

H. Karlic, H. Herrmann, F. Varga, R. Thaler, R. Reitermaier et al., The role of epigenetics in the regulation of apoptosis in myelodysplastic syndromes and acute myeloid leukemia, Critical Reviews in Oncology/Hematology, vol.90, issue.1, pp.1-16, 2014.
DOI : 10.1016/j.critrevonc.2013.10.003

R. Munker, G. Midis, L. Owen-schaub, and M. Andreff, Soluble FAS (CD95) is not elevated in the serum of patients with myeloid leukemias, myeloproliferative and myelodysplastic syndromes, Leukemia, vol.10, pp.1531-1534, 1996.

H. Salih, V. Nuessler, C. Denzlinger, G. Starling, P. Kiener et al., Serum Levels of CD137 Ligand and CD178 are Prognostic Factors for Progression of Myelodysplastic Syndrome, Leukemia & Lymphoma, vol.37, issue.1, pp.301-309, 2004.
DOI : 10.1046/j.1365-2567.1999.00851.x

T. Hirano, N. Hiratsuka, T. Iwahori, K. Oka, and K. Wakasugi, Fas/Fas-ligand expressions in peripheral-blood mononuclear cells of patients with myelodysplastic syndromes, Res Commun Mol Pathol Pharmacol, pp.113-114315, 2003.

P. Gupta, G. Niehans, S. Leroy, K. Gupta, V. Morrison et al., Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival, Leukemia, vol.13, issue.1, pp.44-53, 1999.
DOI : 10.1038/sj.leu.2401233

A. Toma, O. Kosmider, S. Chevret, J. Delaunay, A. Stamatoullas et al., Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion, Leukemia, vol.163, issue.4, 2015.
DOI : 10.1158/1078-0432.CCR-14-1765
URL : https://hal.archives-ouvertes.fr/hal-01321412

A. Giagounidis, U. Platzbecker, U. Germing, K. Götze, P. Kiewe et al., Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1, MDS): Preliminary Results from the Phase 2 PACE-MDS. Blood, p.126, 2015.

E. Frisan, J. Vandekerckhove, A. De-thonel, C. Pierre-eugène, A. Sternberg et al., Defective nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelodysplastic syndromes, Blood, vol.119, issue.6, pp.1532-1574, 2012.
DOI : 10.1182/blood-2011-03-343475
URL : https://hal.archives-ouvertes.fr/hal-00739962

Y. Zermati, C. Garrido, S. Amsellem, S. Fishelson, D. Bouscary et al., Caspase Activation Is Required for Terminal Erythroid Differentiation, The Journal of Experimental Medicine, vol.112, issue.2, pp.247-54, 2001.
DOI : 10.1084/jem.190.12.1725

G. Carlile, D. Smith, and M. Wiedmann, Caspase-3 has a nonapoptotic function in erythroid maturation. Blood, pp.4310-4316, 2004.

E. Gyan, E. Frisan, O. Beyne-rauzy, J. Deschemin, C. Pierre-eugene et al., Spontaneous and Fas-induced apoptosis of low-grade MDS erythroid precursors involves the endoplasmic reticulum, Leukemia, vol.19, issue.10, pp.1864-73, 2008.
DOI : 10.1182/blood-2007-06-096370

A. Hadji, P. Ceppi, A. Murmann, S. Brockway, A. Pattanayak et al., Death induced by CD95 or CD95 ligand elimination. Cell Rep, pp.208-230, 2014.

S. Kleber, I. Sancho-martinez, B. Wiestler, A. Beisel, C. Gieffers et al., Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell, pp.235-283, 2008.

W. Wick, H. Fricke, K. Junge, G. Kobyakov, T. Martens et al., A phase II, randomised, study of weekly APG101 + reirradiation versus reirradiation in progressive glioblastoma. Clin Cancer Res, pp.6304-6317, 2014.

D. Zang, R. Goodwin, M. Loken, E. Bryant, and H. Deeg, Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis, Blood, vol.98, issue.10, pp.3058-65, 2001.
DOI : 10.1182/blood.V98.10.3058

E. Lörsch, T. Luft, S. Fey, J. Obländer, S. Brendel et al., The Fas Ligand Inhibitor APG101 in Transfusion Dependent Patients with Low Risk MDS: Interim Results from a Phase I Study, Blood, vol.124, p.4669, 2014.